Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta et al.|Infectious Diseases and Therapy|2024Cited by 3
Characterization of Patients With Severe Asthma Who Initiated Biologic Treatment Within ≤90 and >90 Days After Biologic EligibilityNatalia Petruski‐Ivleva, Robert Lubwama, J. Ghekas et al.|Unknown|2024Cited by 0